ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL.
Fábio Vieira
FV
Teixeira
Paulo Gustavo
PG
Kotze
Adérson Omar Mourão Cintra
AO
Damião
D000911:Antibodies, Monoclonal; D059451:Biosimilar Pharmaceuticals; D001938:Brazil; D017277:Drug Approval; D005765:Gastrointestinal Agents; D006077:Government Agencies; D006801:Humans; D015212:Inflammatory Bowel Diseases; D000069285:Infliximab
D000911:Antibodies, Monoclonal; D059451:Biosimilar Pharmaceuticals; C000591237:CT-P13; D005765:Gastrointestinal Agents; D000069285:Infliximab